Table 2.
Association of FOXO1, GATA3 and Annexin-1 expression with clinicopathological features of breast cancer
| Variables | FOXO1 | GATA3 | Annexin-1 | |||
|---|---|---|---|---|---|---|
| Positive | Negative | Positive | Negative | Positive | Negative | |
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
| Tumor size | ||||||
| ≤5cm | 38(53.5) | 33(46.5) | 41(78.8) | 11(21.2) | 10(32.3) | 21(67.7) |
| > 5cm | 16(41.0) | 23(59.0) | 27(65.9) | 14(34.1) | 5(16.7) | 25(83.3) |
| N = 110, p=0.093 | N=93, p=0.163 | N = 61, p=0.161 | ||||
| Lymph nodes | ||||||
| Negative | 30(63.8) | 17(36.2) | 35(87.5) | 5(12.5) | 11(44.0) | 14(56.0) |
| Positive | 30(42.9) | 40(57.1) | 33(62.3) | 20(37.7) | 4(11.1) | 32(88.9) |
| N = 117, p=0.038 | N=93,p=0.007 | N = 61, p=0.004 | ||||
| Stage | ||||||
| I/II | 43(57.3) | 32(42.7) | 44(80.0) | 11(20.0) | 10(29.4) | 24(70.6) |
| III/IV | 17(40.5) | 25(59.5) | 24(63.2) | 14(36.8) | 5(18.5) | 22(81.5) |
| N = 117, p=0.087 | N=93,p=0.073 | N = 61, p=0.330 | ||||
| ER | ||||||
| Positive | 23(57.5) | 17 (42.5) | 33(84.6) | 6(15.4) | 1(3.7) | 26(96.3) |
| Negative | 25(41.7) | 35 (58.3) | 40(66.7) | 20(33.3) | 14(41.2) | 20(58.8) |
| N = 100, p=0.122 | N=99,p=0.049 | N = 61, p=0.001 | ||||
| PR | ||||||
| Positive | 23(62.2) | 14 (37.8) | 27(79.4) | 7(20.6) | 0 | 22 (100) |
| Negative | 25(39.7) | 38 (60.3) | 46(70.8) | 19(29.2) | 15 (38.5) | 24(61.5) |
| N = 100, p=0.031 | N=99,p=0.356 | N = 61, p=0.001 | ||||
| HER2 | ||||||
| Positive | 12(33.3) | 24 (66.7) | 13(68.4) | 6(31.6) | 0 | 11(100) |
| Negative | 48(59.3) | 33 (40.7) | 60(75.0) | 20(25.0) | 11(22.0) | 39(78.0) |
| N = 117, p=0.01 | N=99,p=0.560 | N = 61, p=0.051 | ||||
HER2 positive: 3+ positive tested by immunohistochemistry, ER: estrogen receptor, PR: progesterone receptor